Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
|Videos|June 21, 2017
Dr. Verschraegen on Combining Immunotherapy Agents in Lung Cancer
Author(s)Claire Verschraegen, MD
Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.
Advertisement
Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.
Avelumab is different from pembrolizumab (Keytruda) or nivolumab (Opdivo) because it is a PD-L1 monoclonal antibody. Therefore, combining these agents can potentially create a higher benefit for patients.
Advertisement
Related to this article
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Circulating tumor DNA findings from CROWN tied TP53 status and tumor fraction to outcomes with first-line lorlatinib in ALK-positive lung cancer.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
3
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
4
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
5